Karyopharm Therapeutics (KPTI) Cash from Financing Activities (2012 - 2025)

Karyopharm Therapeutics has reported Cash from Financing Activities for 14 years, with the latest figure at $29.7 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities rose 4266.47% year-over-year to $29.7 million; the trailing twelve-month figure through Dec 2025 stood at $30.4 million (up 3117.37% YoY), and the FY2025 full-year result was $30.0 million, down 27.85% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $29.7 million, up from $680000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $155.8 million in Q4 2022, with the low at $16000.0 in Q3 2021.
• Historically, Cash from Financing Activities has averaged $24.9 million across 5 years, with a median of $3.6 million in 2022.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 36143.75% — and 2023, when it slumped 99.83%.
• Karyopharm Therapeutics' Cash from Financing Activities stood at $896000.0 in 2021, then soared by 17293.19% to $155.8 million in 2022, then tumbled by 99.83% to $264000.0 in 2023, then jumped by 157.58% to $680000.0 in 2024, then jumped by 4266.47% to $29.7 million in 2025.
• The last three Cash from Financing Activities figures came in at $29.7 million (Q4 2025), $680000.0 (Q4 2024), and $264000.0 (Q4 2023), per Business Quant data.